USANA Health Sciences (NYSE: USNA) reported Q2 EPS of $0.98, $0.17 worse than the analyst estimate of $1.15. Revenue for the quarter came in at $257.1 million versus the consensus estimate of $284.44 million.

GUIDANCE:

USANA Health Sciences sees FY2017 EPS of $3.50-$3.70, versus the consensus of $3.95. USANA Health Sciences sees FY2017 revenue of $1.015-1.03 million, versus the consensus of $1.07 million.

The Board of Directors has authorized up to $100 million in funding for share repurchases by the Company of its outstanding common stock. This authorization is inclusive of the $35.4 million that was remaining under the prior authorization as of the end of the second quarter. Repurchases may be made from time to time, in the open market, through block trades or otherwise. The number of shares to be purchased and the timing of purchases will be based on market conditions, the level of cash balances, general business opportunities, and other factors. Additional share repurchases would represent upside to the revised EPS outlook the Company issued today.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.